"Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide.
"Refractory" thrombocytopenic purpura treated successfully with cyclophosphamide.
复制标题
用环磷酰胺成功治疗“难治性”血小板减少性紫癜。
DOI：
10.1001/jama.1971.03180160045011
复制
发表时间：
1971
期刊：
影响因子：
--
通讯作者：
J. Penner
中科院分区：
文献类型：
--
作者：
R. Laros;J. Penner
免疫抑制剂在治疗“难治性”血小板减少性紫癜方面已取得不同程度的成功。环磷酰胺是一种有效的免疫抑制剂，具有良好的治疗指数，据我们所知，尚未用于治疗这种疾病。我们的经验包括对 11 名先前接受过皮质类固醇治疗的患者进行的研究。九人的脾脏已被切除。环磷酰胺的每日剂量为50至200mg。 7 名患者获得了良好的缓解，并在停止所有治疗后 10 至 40 个月内保持完全血液学缓解。四名患者的反应良好，血小板水平明显改善，但未达到或保持在正常水平。我们的经验表明，环磷酰胺可以是一种安全有效的方法，可以使常规治疗难治的患者得到缓解。
Immunosuppressive agents have been used with varying success in the treatment of "refractory" thrombocytopenic purpura. Cyclophosphamide, a potent immunosuppressive agent with a good therapeutic index, has, to our knowledge, not been used in the treatment of this disorder. Our experience consists of the study of 11 patients previously treated with corticosteroids. The spleens of nine had been removed. Cyclophosphamide was administered in a daily dose of from 50 to 200 mg. Seven patients had an excellent response and have remained in complete hematologic remission for 10 to 40 months after discontinuation of all therapy. Four patients had a fair response, a definite improvement of platelet levels which have not reached or remained at normal levels. Our experience indicates that cyclophosphamide can be a safe and effective means of inducing remission in patients refractory to conventional therapy.